XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (25,345) $ (29,800)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation, Total 313 281
Amortization of debt discount and issuance costs 2,911 823
Amortization of right-of-use asset 15 0
Interest expense added to loan principal 4,265 4,120
Interest expense added to lease liability 1,227 1,082
Loss on equity method investments 840 776
Loss on debt conversion and extinguishment of debt 1,399 12,394
Compensation charge for stock and share option awards 4,136 1,824
Unrealized gain on warrant derivative liabilities (573) (259)
Changes in operating assets and liabilities:    
Accounts receivable (28) (47)
Prepaid expenses and other current assets (46) (249)
Other assets 206 (214)
Accounts payable 91 226
Lease liabilities (95) 0
Other accrued liabilities 1,041 (1,253)
Net cash used in operating activities (9,643) (10,296)
Cash flows from investing activities:    
Additions to property, plant and equipment and water programs (21,094) (5,103)
Contributions to equity-method investments (435) (2,709)
Net cash used in investing activities (21,529) (7,812)
Cash flows from financing activities:    
Net proceeds from issuance of common stock 32,459 9,808
Net proceeds from the issuance of 8.857% series A cumulative, perpetual preferred stock 54,209 0
Proceeds from the issuance of long-term debt 50,137 150
Issuance costs of long-term debt (2,878) 0
Principal payments on long-term debt (77,559) (30)
Costs of extinguishment of debt (2,525) 0
Taxes paid related to net settlement of equity awards (1,184) 0
Proceeds from the exercise of warrants 4 0
Net cash provided by financing activities 52,663 9,928
Net increase (decrease) in cash, cash equivalents and restricted cash 21,491 (8,180)
Cash, cash equivalents and restricted cash, beginning of period 7,424 15,816
Cash, cash equivalents and restricted cash, end of period $ 28,915 $ 7,636